Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

May 1, 2006

Primary Completion Date

November 30, 2016

Study Completion Date

March 15, 2017

Conditions
Epilepsy
Interventions
DRUG

Ezogabine: USAN Retigabine (International Nonproprietary Name)

Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.

Trial Locations (51)

5000

Fundacion Lennox, Córdoba

Sanatorio del Salvador II, Córdoba

10003

Beth Israel Medical Center, New York

14050

Hospital de Psiquiatria San Fernando, IMSS, Mexico City

CIF BIOTEC, Medica Sur, Tlalpan

17033

Milton S. Hershey Medical Center, Hershey

20817

Mid-Atlantic Epilepsy and Sleep Center, Bethesda

22903

University of Virginia Comprehensive Epilepsy Program, Charlottesville

23298

Virginia Commonwealth University Medical Center, Richmond

28801

Asheville Neurology Specialists, Asheville

32209

University of Florida -- Shands Jacksonville, Jacksonville

33136

University of Miami, Miami

34233

Lovelace Scientific Resources, Sarasota

35294

University of Alabama -- Department of Neurology/Epilepsy Center, Birmingham

35476

Neurology Clinic, Northport

35801

North Alabama Neuroscience Research Associates, Huntsville

37212

Vanderbilt University Medical Center, Nashville

40536

University of Kentucky, Lexington

42690

Instituto Nacional de Neurologia y Neurocirugia, La Fama

43614

Medical University of Ohio at Toledo, Toledo

44280

Antiguo Hospital Civil de Guadalajara, Guadalajara

48202

Henry Ford Hospital, Detroit

50010

McFarland Clinic, Ames

55102

Minnesota Epilepsy Group, P.A., Saint Paul

63017

The Comprehensive Epilepsy Care Center for Children and Adults, Chesterfield

64000

Hospital y Clinica OCA S.A. de C.V., Monterrey

72205

Clinical Trials Inc., Little Rock

75230

Medical City Dallas Hospital, Dallas

Neurological Clinic of Texas, Dallas

77030

Memorial Hermann Hospital, Houston

78250

Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí City

80010

University of Colorado Department Of Neurology, Denver

80918

Delta Waves, Colorado Springs

85013

Barrow Neurological Institute, Phoenix

90033

University of Southern California -- Keck School of Medicine, Los Angeles

90073

West Los Angeles VA Healthcare Center, Los Angeles

92037

UCSD Thornton Hospital, La Jolla

97062

Oregon Neurology PC, Tualatin

C1181ACH

Hospital Italiano de Buenos Aires, Capital Federal

Unknown

"Hospital General de Agudos Dr. J.M. Ramos Mejia", Capital Federal

"Hospital General de Agudos Dr. Teodoro Alvarez", Capital Federal

X5016KEH

Hospital Privado Centro Medico de Cordoba, Córdoba

40110-060

Hospital Universitario Prof Edgard Santos -- UFBA, Salvador

14048-900

Hospital das Clinicas de Ribeirao Preto -- Universidade de Sa Neurologia, Ribeirão Preto

04024 002

Hospital Sao Paulo -- Escola Paulista de Medicina -- UNIFESP, São Paulo

05403-900

Hospital das Clinicas da Fac de Medicina de Sao Paulo, São Paulo

T2N 2T9

Foothills Medical Center, Calgary

T5G 0B7

Glenrose Rehabilitation Center, Edmonton

A1B 3V6

Health Sciences Centre, St. John's

H2L 4M1

CHUM -- Hôpital Notre-Dame, Montreal

03229

Centro Medico, Mexico City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY